LOUISVILLE, Ky.--(BUSINESS WIRE)--US WorldMeds, LLC, today announced the launch of a final Phase 3 clinical trial to investigate the use of MYOBLOC® (rimabotulinumtoxinB) Injection to obtain FDA approval of an indication for sialorrhea, commonly known as “drooling.” This “drooling” is common in patients who may have difficulty swallowing due to neurological disorders such as Parkinson’s disease, Lou Gehrig’s disease, stroke, brain injury, and cerebral palsy. Drooling can also be caused by oral cancers or as a side effect to certain medications, such as drugs used to treat Schizophrenia. This disorder can be socially debilitating, but evidence suggests that the swallowing difficulty and untreated ‘drooling’ may potentially contribute to other more serious medical complications, such as skin breakdown and respiratory infections. Currently, there is no approved pharmacological treatment for ‘drooling’ in adults.
Help employers find you! Check out all the jobs and post your resume.
